Autoimmune disorders: Nail signs and therapeutic approaches

Dermatologic Therapy

Volumn 20, Issue 1, 2007, Pages 17-30

  Sherber, Noëlle S ^a   Wigley, Fredrick M ^b   Scher, Richard K ^a  

^a Department of Medicine   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Digital ulcers; Nail fold capillaroscopy; Raynaud's phenomenon; Scleroderma

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BACITRACIN; BLEOMYCIN; BOSENTAN; BUPIVACAINE; CALCIUM CHANNEL BLOCKING AGENT; CISPLATIN; CLONIDINE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; FELODIPINE; FLUOXETINE; ISRADIPINE; LIDOCAINE; NARCOTIC AGENT; NIFEDIPINE; NITRATE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PRAZOSIN; PROSTAGLANDIN; PSEUDOMONIC ACID; SEROTONIN AGONIST; SILDENAFIL; UNINDEXED DRUG; UNIPROST; VINCRISTINE;

ARTICLE; AUTOIMMUNE DISEASE; BLEEDING; BLOOD VESSEL INJURY; CAPILLAROSCOPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYANOSIS; DERMATOMYOSITIS; DIFFERENTIAL DIAGNOSIS; DRUG DOSE TITRATION; EPILUMINESCENCE MICROSCOPY; GANGRENE; HUMAN; INJECTION SITE PAIN; ISCHEMIA; KERATOSIS; LEUKODERMA; MICROANGIOPATHY; NAIL DISEASE; OPHTHALMOSCOPY; PARONYCHIA; PETECHIA; RAYNAUD PHENOMENON; SCLERODERMA; SYMPATHECTOMY; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCER; VASCULAR DISEASE;

AUTOIMMUNE DISEASES; DERMATOMYOSITIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; NAIL DISEASES; SCLERODERMA, SYSTEMIC;

EID: 34147131198     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2007.00108.x     Document Type: Article

References (26)

1. Cutolo M, Grassi W, Cerinic MM. Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum 2003: 48: 3023-3030.
2. Lombard WP. The blood pressure in the arterioles, capillaries, and small veins of the human skin. Am J Physiol 1911: 29: 355-362.
3. Cutolo M, Sulli A, Secchi ME, Paolino S, Pizzorni C. Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement? Rheumatology 2006: 45: iv43-iv46.
4. Nagy Z, Czirjak L. Nailfold digital capillaroscopy in 447 patients with connective tissue disease and Raynaud's disease. J Eur Acad Dermatol Venereol 2004: 18: 62-68.
5. Maricq HR. Comparison of quantitative and semiquantitative estimates of nailfold capillary abnormalities in scleroderma spectrum disorders. Microvasc Res 1986: 32: 271-276.
6. Bergman R, Sharony L, Schapira D, Nahir MA, Balbir-Gurman A. The handheld dermatoscope as a nail-fold capillaroscopic instrument. Arch Dermatol 2003: 139: 1027-1030.
7. Anderson ME, Allen PD, Moore T, Villier V, Taylor CJ, Herrick AL. Computerized nailfold video capillaroscopy - a new tool for assessment of Raynaud's phenomenon. J Rheumatol 2005: 32: 841-848.
8. Houtman PM, Kallenberg CG, Fidler V, Wouda AA. Diagnostic significance of nailfold capillary patterns in patients with Raynaud's phenomenon - an analysis of patterns discriminating patients with and without connective tissue disease. J Rheumatol 1986: 13: 556-563.
9. Bredemeier M, Xavier RM, Capobianco KG, et al. Nailfold capillary microscopy can suggest pulmonary disease activity in systemic sclerosis. J Rheumatol 2004: 31: 286-294.
10. Cheng KS, Tiwari A, Boutin A, et al. Differentiation of primary and secondary Raynaud's disease by carotid arterial stiffness. Eur J Vasc Endovasc Surg 2003: 25: 336-341.
11. Rich P, Scher RK. An atlas of diseases of the nail. New York: Parthenon Publishing, 2003.
12. Scher RK, Daniel CR III. Nails: therapy, diagnosis, surgery, 3rd edn. Philadelphia: W.B. Saunders Company, 2005.
13. Scher RK, Tom DW, Lally EV, Bogaars HA. The clinical significance of periodic acid-Schiff-positive deposits in cuticle-proximal nail fold biopsy specimens. Arch Dermatol 1985: 121: 1406-1409.
14. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survivial in 1012 Italian patients. Medicine 2002: 81: 139-153.
15. Hummers LK, Wigley FM. Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am 2003: 29: 293-313.
16. Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ. Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 1992: 35: 688-693.
17. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006: 367: 1683-1691.
18. Chotani MA, Flavahan S, Mitra S, Daunt D, Flavahan NA. Silent α2C-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 2000: 278: H1075-H1083.
19. Flavahan NA, Flavahan S, Liu Q, et al. Increased α2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 2000; 43: 1886-1890.
20. Sule SD, Wigley FM. Treatment of scleroderma: an update. Expert Opin Investig Drugs 2003: 12: 471-482.
21. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001: 44: 1841-1847.
22. Korn JH, Mayer M, Cerinic MM, et al. Digital ulcers in systemic sclerosis - prevention by treatment with Bosentan, an oral endothelin receptor antagonist. Arthritis Rheumatism 2004: 50: 3985-3993.
23. Moore TL, Vail A, Herrick AL. Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon. Rheumatology 2007: 46: 363-364.
24. Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005: 112: 2980-2985.
25. Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 2001: 40: 1038-1043.
26. Chung L, Fiorentino D. A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. J Am Acad Dermatol 2006: 54: 880-882.